Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KGPEA
ADC Name
CTLA4-IR700
Synonyms
CTLA4-IRDye700DX
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Oropharyngeal cancer [ICD11:2B6A]
Investigative
Antibody Name
Anti-CTLA4 mAb clone 9D9
  Antibody Info 
Antigen Name
Cytotoxic T-lymphocyte protein 4 (CTLA4)
  Antigen Info 
Payload Name
IRDye 700DX
  Payload Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through nucleophilic lysines.
Combination Type
Sarotalocan
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI) 
≈ 38
%
Oropharyngeal cancer PDX model (PDX: mEERL-hEGFR)
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 38.00% Positive CTLA4 expression (CTLA4 +++/++)
Method Description
Mice with tumors reaching approximately 50-100 mm3 in volume were used for the experiments. Mice were monitored each day and tumor volume (length x width2 x 0.5) was measured twice a week until the tumor volume reached 2,000 mm3.
In Vivo Model Oropharyngeal cancer PDX model (PDX: mEERL-hEGFR)
References
Ref 1 Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. Mol Cancer Ther. 2021 Nov;20(11):2262-2273. doi: 10.1158/1535-7163.MCT-21-0470. Epub 2021 Sep 13.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.